EGFR and metastatic colorectal cancer: The overall survival (OS) time of patients with metastatic colorectal cancer (CRC) has increased owing to novel therapeutic strategies combining chemotherapy with monoclonal antibodies against vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR).